AbbVie touts Rinvoq win in giant cell arteritis, potentially teeing up another label expansion

On Thursday, AbbVie said that Rinvoq, also known as upadacitinib, met its primary endpoint in the SELECT-GCA trial in patients with giant cell arteritis (GCA). Specifically, 46% of patients treated with the AbbVie drug at the 15 mg dose—plus a 26-week steroid taper regimen—achieved sustained remission from week 12 through week 52.